Researchers develop scalable method to generate key immune cells for cancer therapy

Researchers at the Center for Regenerative Medicine (CReM) in Boston have created a method to efficiently produce CD4+ helper T cells from induced pluripotent stem cells (iPSCs). This breakthrough could lead to widely available, off-the-shelf CAR-T cell therapies for treating various types of cancer. Currently, each patient's CAR-T therapy is costly and time-consuming due to the need for personalized production. iPSCs, derived from adult skin or blood cells, could revolutionize the process by enabling large-scale, ready-to-use T cell production.

The challenge has been generating functional CD4+ helper T cells through a key molecular signaling pathway called Notch. Researchers discovered that by removing Notch signaling during later T cell maturation stages while simultaneously reducing anti-T cell receptor signaling, they could successfully produce CD4+ T cells in large quantities.

The team's protocol is simple, efficient, and scalable, paving the way for more accessible and affordable cancer treatments.